title: [Low Intensity Anticoagulation Therapy for Chinese Population with Heart Valve Replacement--3 000 Cases Follow-up].
abstract: OBJECTIVE
  To investigate the effect of low-intensity anticoagulation therapy for Chinese population with heart valve replacement.
  
  
  METHODS
  From January 2011 to March 2012, 3 000 patients with heart valve replacement in Fuwai Hospital and West China Hospital were followed-up for 1 year, the method and intensity of postoperative anticoagulation, as well as the complications were studied and analyzed.
  
  
  RESULTS
  The rate of follow-up was 88.57%, and the cumulative follow-up was 1 726.1 patient-years (Pty). The mean oral warfarin dosage was (2.68 ± 6.45) mg/d, and the mean INR values of the patients treated in Fuwai Hospital and West China Hospital were 2.01 ± 1.10 and 186 ± 0.69 respectively (total 54 379 samples). The total rates of anticoagulation complication and mortality were 5.79% Pty and 0.12% Pty respectively, among which the morbidity and mortality of hemorrhage were 3.59% Pty and 0.12% Pty respectively, while the morbidity and mortality of thromboembolism were 2.03% Pty and 0.00% Pty respectively. There are no significant differences of actual anticoagulation intensity (P = 0.28)and the complication rates between the two hospitals .
  
  
  CONCLUSIONS
  The optimal intensity scope (INR) of 1.5-2.5 (mean 1.8-2.0) is safe and efficient for Chinese patients with prosthetic heart valves, and no significant regional difference in the intensity of anticoagulation therapy required.
authors.forename: Jian-ping
authors.initials: JP
authors.lastname: Xu
authors.forename: Ying-kang
authors.initials: YK
authors.lastname: Shi
authors.forename: Li
authors.initials: L
authors.lastname: Dong
authors.forename: Yu
authors.initials: Y
authors.lastname: Wei
authors.forename: Bo
authors.initials: B
authors.lastname: Fu
authors.forename: Ruo-fan
authors.initials: RF
authors.lastname: Liu
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D044466:Asian People; D002681:China; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation; D006470:Hemorrhage / Q000401:mortality; D006801:Humans; D011184:Postoperative Period; D013923:Thromboembolism / Q000401:mortality; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin